Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lirilumab combo shows early promise in SCCHN

Innate Pharma S.A. (Euronext:IPH) reported preliminary data from a Phase I/II trial of lirilumab (IPH2102) plus PD-1 inhibitor Opdivo nivolumab that suggest the

Read the full 230 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE